A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: Differences in action in vivo and in vitro

Molecular Biology Reports

Volumn 37, Issue 4, 2010, Pages 1801-1814

  Liu, Wai M ^a   Laux, Holger ^b   Henry, Jake Y ^a   Bolton, Thomas B ^b   Dalgleish, Angus G ^a   Galustian, Christine ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Colorectal cancer; Gene expression; Immunomodulatory drug; In vitro; In vivo

Indexed keywords

CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CONTACTIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 1; G PROTEIN COUPLED RECEPTOR; GELATINASE B; GLYCEROL KINASE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 2; INTERLEUKIN 6; LENALIDOMIDE; LIPOCALIN; MITOGEN ACTIVATED PROTEIN KINASE 1; NOTCH RECEPTOR; POMALIDOMIDE; PROTEIN BAX; PROTEIN BCL 2; RING FINGER PROTEIN; SCATTER FACTOR; SEMINAL VESICLE SECRETORY PROTEIN; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN RECEPTOR 1; WNT PROTEIN; BIOLOGICAL MARKER; DRUG DERIVATIVE; IMMUNOLOGIC FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL; CELL ADHESION; CELL COMMUNICATION; COLORECTAL CANCER; CONTROLLED STUDY; DNA MICROARRAY; DRUG MECHANISM; FEMALE; GENE CLUSTER; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TRANSLATION INITIATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CLUSTER ANALYSIS; COLORECTAL TUMOR; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; LYMPHOCYTE; METABOLISM; QUALITY CONTROL; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR GENE; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CELL LINE, TUMOR; CLUSTER ANALYSIS; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; IMMUNOLOGIC FACTORS; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THALIDOMIDE;

EID: 77953171709     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-009-9614-3     Document Type: Article

References (33)

1. Chanan-Khan AA, Cheson BD (2008) Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 26:1544-1552. doi:10.1200/JCO.2007.14.5367
2. Falco P, Cavallo F, Larocca A et al (2008) Lenalidomide and its role in the management of multiple myeloma. Expert Rev Anticancer Ther 8:865-874. doi:10.1586/14737140.8.6.865
3. Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4:314-322. doi:10.1038/nrc1323
4. Dredge K, Horsfall R, Robinson SP et al (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69:56-63. doi:10.1016/j.mvr.2005.01.002
5. Dredge K, Marriott JB, Macdonald CD et al (2002) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87:1166-1172. doi:10.1038/sj.bjc.6600607
6. Shalapour S, Zelmer A, Pfau M et al (2006) The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo. Clin Cancer Res 12:5526-5532. doi:10.1158/1078-0432.CCR-06-0719
7. Verhelle D, Corral LG, Wong K et al (2007) Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 67:746-755. doi:10.1158/0008-5472.CAN-06-2317
8. Breitkreutz I, Raab MS, Vallet S, et al. (2008) Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22:1925-1932
9. Liu WM, Strauss SJ, Chaplin T et al (2004) s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. Hematol J 5:247-254. doi:10.1038/sj.thj.6200351
10. Galustian C, Meyer B, Labarthe MC, et al. (2008) The anticancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58:1033-1045
11. Liu WM, Henry JY, Meyer B, Bartlett JB, Dalgleish AG, Galustian C (in press) Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Brit J Cancer
12. Koh KR, Janz M, Mapara MY et al (2005) Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood 105:3833-3840. doi:10.1182/blood-2004-03-0828
13. Ota K, Matsui M, Milford EL et al (1990) T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346:183-187. doi:10.1038/346183a0
14. Mastronardi FG, Moscarello MA (2005) Molecules affecting myelin stability: A novel hypothesis regarding the pathogenesis of multiple sclerosis. J Neurosci Res 80:301-308. doi:10.1002/jnr.20420
15. Sastry PS (1999) Inhibition of TNF-alpha synthesis with thalidomide for prevention of acute exacerbations and altering the natural history of multiple sclerosis. Med Hypotheses 53:76-77.doi:10.1054/mehy.1997.0719
16. Radtke F, Wilson A, Mancini SJ et al (2004) Notch regulation of lymphocyte development and function. Nat Immunol 5:247-253. doi:10.1038/ni1045
17. Staal FJ, Clevers HC (2005) WNT signalling and haematopoiesis: A WNT-WNT situation. Nat Rev Immunol 5:21-30. doi:10.1038/nri1529
18. Li JL, Harris AL (2005) Notch signaling from tumor cells: A newmechanism of angiogenesis. Cancer Cell 8:1-3. doi:10.1016/j.ccr.2005.06.013
19. Katoh M (2007) Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem Cell Rev 3:30-38. doi:10.1007/s12015-007- 0006-6
20. Taylor KL, Henderson AM, Hughes CC (2002) Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/ KDR expression. Microvasc Res 64:372-383. doi:10.1006/mvre.2002.2443
21. Katoh M, Katoh M (2007) WNT signaling pathway and stem cell signaling network. Clin Cancer Res 13:4042-4045. doi:10.1158/1078-0432.CCR-06-2316
22. Aragon-Ching JB, Li H, Gardner ER et al (2007) Thalidomide analogues as anticancer drugs. Recent Patents Anticancer Drug Discov 2:167-174
23. Wu L, Adams M, Carter T et al (2008) Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20 + tumor cells.Clin Cancer Res 14:4650-4657. doi:10.1158/1078-0432.CCR-07-4405
24. Mitsiades N, Mitsiades CS, Poulaki V et al (2002) Apoptotic ignaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 99:4525-4530. doi:10.1182/blood.V99.12.4525
25. Hansen JM, Harris C (2004) A novel hypothesis for thalidomideinduced limb teratogenesis: redox misregulation of the NF-kappaB pathway. Antioxid Redox Signal 6:1-14. doi:10.1089/152308604771978291
26. Li H, Lin X (2008) Positive and negative signaling components involved in TNFalpha-induced NF-kappaB activation. Cytokine 41:1-8. doi:10.1016/j.cyto. 2007.09.016
27. Elowitz MB, Levine AJ, Siggia ED et al (2002) Stochastic gene expression in a single cell. Science 297:1183-1186. doi:10.1126/science.1070919
28. Neildez-Nguyen TM, Parisot A, Vignal C et al (2008) Epigenetic gene expression noise and phenotypic diversification of clonal cell populations. Differentiation 76:33-40
29. Bergers G, Brekken R, McMahon G et al (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737-744. doi:10.1038/35036374
30. Liu WM (2008) Enhancing the cytotoxic activity of novel targeted therapies-is there a role for a combinatorial approach? Curr Clin Pharmacol 3:108-117. doi:10.2174/157488408784293714
31. Clarke PA, te Poele R, Workman P (2004) Gene expression microarray technologies in the development of new therapeutic agents. Eur J Cancer 40:2560-2591. doi:10.1016/j.ejca.2004.07.024
32. Burington B, Barlogie B, Zhan F et al (2008) Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma. Clin Cancer Res 14:4821-4829. doi:10.1158/1078-0432.CCR-07-4568
33. Vallet S, Palumbo A, Raje N et al (2008) Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma 49:1238-1245. doi:10.1080/10428190802005191